| Authors: |
Luethi D; Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland. dino.luethi@unibas.ch., Glatfelter GC; Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US., Pottie E; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium., Sellitti F; Neuropharmacology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Maitland AD; Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US., Gonzalez NR; Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US., Kryszak LA; Translational Analytical Core, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US., Jackson SN; Translational Analytical Core, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US., Hoener MC; Neuroscience Research, pRED, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd, Basel, Switzerland., Stove CP; Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium., Liechti ME; Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland., Smieško M; Computational Pharmacy, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.; Société des Produits Nestlé, Nestlé Research, Lausanne, Switzerland., Baumann MH; Designer Drug Research Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, MD, US., Simmler LD; Neuropharmacology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland., Rudin D; Psychopharmacology Research, Department of Biomedicine, University Hospital Basel and University of Basel, Basel, Switzerland. |
